The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $100.56

Today's change-1.17 -1.15%
Updated February 11 10:00 AM EST. Delayed by at least 15 minutes.
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $100.56

Today's change-1.17 -1.15%
Updated February 11 10:00 AM EST. Delayed by at least 15 minutes.

Johnson & Johnson crosses below 50-day moving average

Johnson & Johnson is lower today, dropping (U.S.)$1.17 or 1.15% to (U.S.)$100.56 and crossing below its 50-day moving average. Shares have lost 3.21% over the last five days, but are unchanged over the last year to date. This security has outperformed the S&P 500 by 11.54% during the last year.

Key company metrics

  • Open(U.S.) $100.46
  • Previous close(U.S.) $101.73
  • High(U.S.) $100.90
  • Low(U.S.) $99.98
  • Bid / Ask(U.S.) $100.55 / (U.S.) $100.57
  • YTD % change-2.10%
  • Volume939,350
  • Average volume (10-day)11,910,535
  • Average volume (1-month)10,488,324
  • Average volume (3-month)8,581,224
  • 52-week range(U.S.) $81.79 to (U.S.) $105.49
  • Beta0.63
  • Trailing P/E18.36×
  • P/E 1 year forward15.61×
  • Forward PEG2.99×
  • Indicated annual dividend(U.S.) $3.00
  • Dividend yield2.98%
  • Trailing EPS(U.S.) $5.48
Updated February 11 10:00 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+21.99%

Based on its net profit margin of 21.99%, Johnson & Johnson is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.96%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJan 03, 201601/03/2016Sep 27, 201509/27/2015Jun 28, 201506/28/2015Mar 29, 201503/29/2015
Revenue17,81117,10217,78717,374
Total other revenue--------
Total revenue17,81117,10217,78717,374
Gross profit12,13811,87812,43012,092
Total cost of revenue5,6735,2245,3575,282
Total operating expense14,05312,98012,04611,799
Selling / general / administrative5,8915,0815,3844,847
Research & development2,8642,1542,1291,899
Depreciation / amortization--------
Interest expense (income), net operating--123131138
Unusual expense (income)7231000
Other operating expenses, total-1,205412-1,055-264
Operating income3,7584,1225,7415,575
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax3,7584,1225,7415,575
Income after tax3,2153,3584,5164,320
Income tax, total5437641,2251,255
Net income3,2153,3584,5164,320
Total adjustments to net income--------
Net income before extra. items3,2153,3584,5164,320
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items3,2153,3584,5164,320
Inc. avail. to common incl. extra. items3,2153,3584,5164,320
Diluted net income3,2153,3584,5164,320
Dilution adjustment000--
Diluted weighted average shares2,8032,8072,8122,826
Diluted EPS excluding extraordinary itemsvalue per share1.151.201.611.53
Dividends per sharevalue per share0.750.750.750.70
Diluted normalized EPSvalue per share1.381.201.611.38